Loss Of L8 million In 1st Quarter For British Biotech

29 September 1996

British Biotech made a loss in the first quarter of the 1996/97 fiscal year ended July 31 of L8 million ($12.5 million), compared with L7 million a year earlier, which the company says was well within budget. Turnover was L530,000, compared with L344,000 a year earlier. The revenues came from a L300,000 milestone payment in respect of BB10153 from JT Pharmaceuticals, and from the continuing biological research agreement with R&D Systems.

R&D expenditure for the quarter was L7.9 million, up 23.4%. BB said that the rise was primarily due to the increased development resources supporting the expanding clinical programs for marimastat and lexipafant both in the USA and in Europe.

During the quarter, BB completed a one for eight rights issue raising around L143 million (Marketletters passim). The company said that the balance sheet was significantly strengthened at the end of the quarter with cash reserves in excess of L200 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.